tbuckley/cabot-search huggingface dataset:
Selective Blockade of Metabotropic Glutamate Receptor by MPEP Protects against Hepatic Cold Ischemia and Reperfusion Injury
Authors: C. Berardo, L.G. Di Pasqua, V. Rizzo, P. Richelmi, F. Nicoletti, A. Ferrigno, M. Vairetti
Journal: Journal of Hepatology (2016)
Treatment Outcomes for Hepatitis C Genotype 1 Infection with Direct Acting Antivirals: Data from the German Hepatitis C-Registry
Authors: S. Mauss, P. Buggisch, K.H.W. Böker, E. Schott, H. Klinker, R. Günther, H. Pfeiffer-Vornkahl, T. Berg, C. Sarrazin, D. Hüppe, M.P. Manns
Journal: Journal of Hepatology (2016)
Rational combination of a novel cell cycle inhibitor ON01910.Na with gemcitabine in patients with advanced solid tumors.
Authors: W. Ma, S. Mani, E. Freas, G. K. Dy, M. H. Ghalib, W. A. Messersmith, S. Bellemarre, F. Wilhelm, A. A. Adjei, A. Jimeno
Journal: Journal of Clinical Oncology (2010)

e13515 Background: ON01910.Na (ON) is a novel, multitargeted mitotic inhibitor of several regulatory enzymes including polo-like kinase 1 (Plk1) and PI-3 kinases. We documented that ON has a synergistic effect when combined with gemcitabine (G) in nonclinical studies (Jimeno et al, 2008, 2009). This is a phase I dose escalation study to determine the DLT, MTD, pharmacokinetic (PK) profile and antitumor activity of ON combined with G. Methods: Patients had histologically confirmed, solid tumors refractory to standard therapy. Gemcitabine was administered as a 30-min infusion on days 1, 8 and 15 of a 28-day cycle. ON01910.Na, was administered as i) a 2-h infusion on days 1, 4, 8, 11, 15, and 18 in the first study, and ii) a weekly 24-h infusion in the second study. Assessments include safety, response, pharmacokinetic (PK) interaction studies at the MTD, and pharmacodynamics (PD) in tumor at the MTD. A dose confirmation cohort of up to 12 patients will be treated at the MTD. Results: 20 pts (age 26-74; median ECOG PS 1) have received 53 cycles (5 pts ongoing): 17 in the 2-h infusion schedule (G/ON per m2: 750/600 n=5; 750/1,200 n=4; 1,000/600 n=5; 1,000/1,200 n=3), and 3 in the 24-h schedule (G/ON per m2: 1,000/1,200 n=2; 1,000/250 n=1). Toxicities have been those expected from G, with thrombocytopenia, neutropenia, elevated AST/ALT, nausea, vomiting, and fatigue. No DLTs per protocol have been documented, and accrual to G/ON 1,000/1,800 (2-h infusion) dose level is ongoing. Antitumor activity was seen in a G-pretreated Hodgkin's disease pt (PR, 50%), 2 G-naïve pancreatic ca pts (MR, 10% and 13% at cycle 4, both ongoing), and 2 ovarian ca pts (1 G-pretreated, with 50% decrease in CA125; 1 G-naïve, with 50% decrease in CA125 and MR with 12% regression). In the 24-h schedule a gastric ca pt had a MR by RECIST, and accrual is ongoing. Conclusions: This work represents the translation of a rational combinatorial strategy. Gemcitabine combined with ON01910.Na with 2 different schedules, is well tolerated. Activity in G-pretreated pts suggests proof of principle and rationale for exploration in G refractory patients. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Onconova Therapeutics, Inc. Onconova Therapeutics, Inc. Onconova Therapeutics, Inc.
Abstract P3-07-11: Retrospective database review of outcomes in invasive lobular carcinoma and invasive ductal carcinoma of the breast
Authors: Y-C Shih, P Dillon
Journal: Cancer Research (2012)

Abstract Background. Invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC) are histologically distinct breast cancer subtypes. While ILC and IDC have similar disease-free survival (DFS) and overall survival (OS), the patterns of metastatic recurrence are suspected to differ due to differing adhesion markers. Methods. Retrospective review of a cohort of breast cancer patients treated at a tertiary academic medical center from May 1999 to April 2012 was performed. Demographic, pathologic, treatment and follow-up data were collected from a cancer database and the institutional medical records. Results. There were 179 ILC and 358 IDC (1:2 stage-matched) patients in the study period. Mean age (59 vs. 58 years), gender, race (88% vs. 80% Caucasian), menopause state (71% vs. 66% post-menopausal), and family history (48% vs. 42% positive for breast cancer) were similar in the two groups. Median follow-up was 4.7 years. ILC patients had more negative mammograms upon diagnosis (6.8% vs. 1.4%, p = 0.001), and their breast cancers were more likely to be hormone-receptor-positive/HER2-negative (90% vs. 69%, p &amp;lt; 0.00001). The recurrence rate was the same between ILC and IDC. ILC recurred more often in the abdominal cavity (24.3% vs. 4.1%, p = 0.001), and it recurred similarly to IDC in other sites (bone, lung, liver, central nervous system, and local). Both groups received similar treatments, including number of surgical resections (1.3), positive margins (17%), breast-conservation rate (42% in ILC vs. 49% in IDC), systemic treatment (91% vs. 88%), and taxane use during chemotherapy (71% vs. 69%). The DFS (10.6 vs. 11.4 years), OS (10.2 vs. 11.9 years), and breast-cancer-specific OS (11 vs. 13 years) were not statistically different. In a subgroup analysis, stage IV ILC patients had worse overall survival than stage IV IDC patients (2.9 vs. 6.8 years, p = 0.039). On multivariate analysis, age, stage of disease, hormone receptor status, and systemic therapy were associated with survival, but histology was not. Conclusions. Compared to ductal breast cancers, lobular breast cancers recur more often in the abdominal cavity. Both ILC and IDC have comparable surgical and medical treatment outcomes, including resection number, positive margin of resection, breast conservation rate, recurrence rate, and survival. Citation Information: Cancer Res 2012;72(24 Suppl):Abstract nr P3-07-11.
Reactivation of oncogene-induced senescence in <i>KRAS</i> mutant non-small cell lung cancer by inhibition of <i>TWIST1</i>.
Authors: T. F. Burns, I. Dobromilskaya, S. Murphy, S. Thiyagarajan, S. Das, P. T. Tran, C. M. Rudin
Journal: Journal of Clinical Oncology (2011)

10591 Background: A large fraction of non-small cell lung cancers (NSCLC) have mutant KRAS, which predicts poor response to current cytotoxic therapy and portends a poor prognosis. Reactivation of senescence in KRAS mutant NSCLC may be an effective therapeutic strategy. We previously have shown that Twist1 cooperates with mutant KRAS to induce adenocarcinoma of the lung in mouse models and inhibition of Twist1 in these models leads to reactivation of KRAS induced senescence. In the current study, we explore whether TWIST1 plays a critical role in KRAS mutant human NSCLC. Methods: TWIST1 mRNA levels were examined through quantitative PCR. TWIST1, p53 and p21 were targeted with shRNAs. Reactivation of senescence was assessed through senescence associated beta-galactosidase staining (SA-β-Gal) and immunobloting (p21 and p27). Growth inhibition was determined through the crystal violet colony formation assay in vitro and xenografts experiments in vivo. Results: TWIST1 was overexpressed in 61% of the 164 human lung tumor samples examined. Silencing of TWIST1 in the KRAS mutant NSCLC cell line, H460, led to dramatic growth inhibition and induction of the senescence associated markers, p21, p27, and SA-β-Gal staining. Similar growth inhibition and induction of senescence were observed in six additional KRAS mutant NSCLC cell lines. Interestingly, growth inhibition by silencing of TWIST1 was independent of p53 or p16 mutational status. Silencing of p53 in two p53 wildtype NSCLC cell lines could not rescue loss of TWIST1 expression. Similar results were seen for inhibition of p21. To extend these observations in vivo, A549 cells containing a doxycycline-inducible shRNA against TWIST1 were implanted in NOD-SCID mice. Significant growth inhibition of established xenograft tumors was observed upon the addition of doxycycline. Conclusions: We have demonstrated TWIST1 is frequently overexpressed in human lung tumors. Furthermore, inhibition of TWIST1 in KRAS mutant lung cancer leads to reactivation of OIS and dramatic growth inhibition independent of the presence of p53 or p16. Together these findings suggest that inhibition of TWIST1 in KRAS mutant NSCLC represents a novel and exciting therapeutic strategy.
Distribution and Clinical Signs of Venous, Arterial and Intracardiac Clots After Pediatric Cardiac Surgery.
Authors: Leonardo R. Brandao, Cedric Manlhiot, Ines B. Menjak, Anthony Chan, Caitlin Carew, Colleen E. Gruenwald, Steven M. Schwartz, Ben V. Sivarajan, Brian W. McCrindle
Journal: Blood (2009)
Sarcopenia as a Prognostic Factor in Patients with Extensive Fibrosis/Cirrhosis and Hepatocellular Carcinoma
Authors: E. Gigante, M. Bouattour, L. Castera, M. Ronot, O. Bruno, C. Francoz, V. Vilgrain, O. Soubrane, F. Durand
Journal: Journal of Hepatology (2016)
Le typhus murin ré-émerge t-il au Portugal ?
Authors: F Bacellar, I Lencastre, A R Filipe
Journal: Eurosurveillance (1998)

Le typhus murin ou typhus endemique est une maladie infectieuse due a Rickettsia typhi (parfois appele R. mooseri), cliniquement tres similaire au typhus epidemique.
Interferon Sparing Directly Acting Antiviral (DAA) Therapy for HCV in Decompensated Cirrhosis: Natural Killer Cell (NK) Phenotype is Associated with Non-Response
Authors: K. Childs, E. Merritt, W. Swanson, A. Sanchez-Fueyo, M. Martinez-Llordella, K. Agarwal, I. Carey
Journal: Journal of Hepatology (2016)
Anti–TGF-β1 Antibody Therapy in Patients with Diabetic Nephropathy
Authors: James Voelker, Paul H. Berg, Matthew Sheetz, Kevin Duffin, Tong Shen, Brian Moser, Tom Greene, Samuel S. Blumenthal, Ivan Rychlik, Yoram Yagil, Philippe Zaoui, Julia B. Lewis
Journal: Journal of the American Society of Nephrology (2016)

TGF- β has been implicated as a major pathogenic factor in diabetic nephropathy. This randomized, double-blind, phase 2 study assessed whether modulating TGF- β 1 activity with a TGF- β 1–specific, humanized, neutralizing monoclonal antibody (TGF- β 1 mAb) is safe and more effective than placebo in slowing renal function loss in patients with diabetic nephropathy on chronic stable renin-angiotensin system inhibitor treatment. We randomized 416 patients aged ≥25 years with type 1 or type 2 diabetes, a serum creatinine (SCr) level of 1.3–3.3 mg/dl for women and 1.5–3.5 mg/dl for men (or eGFR of 20–60 ml/min per 1.73 m 2 ), and a 24-hour urine protein-to-creatinine ratio ≥800 mg/g to TGF- β 1 mAb (2-, 10-, or 50-mg monthly subcutaneous dosing for 12 months) or placebo. We assessed a change in SCr from baseline to 12 months as the primary efficacy variable. Although the Data Monitoring Committee did not identify safety issues, we terminated the trial 4 months early for futility on the basis of their recommendation. The placebo group had a mean±SD change in SCr from baseline to end of treatment of 0.33±0.67 mg/dl. Least squares mean percentage change in SCr from baseline to end of treatment did not differ between placebo (14%; 95% confidence interval [95% CI], 9.7% to 18.2%) and TGF- β 1 mAb treatments (20% [95% CI, 15.3% to 24.3%], 19% [95% CI, 14.2% to 23.0%], and 19% [95% CI, 14.0% to 23.3%] for 2-, 10-, and 50-mg doses, respectively). Thus, TGF- β 1 mAb added to renin-angiotensin system inhibitors did not slow progression of diabetic nephropathy.
Differences in autonomy of humans and ultrasocial insects
Authors: Marek Vranka, Štěpán Bahník
Journal: Behavioral and Brain Sciences (2016)

The target article is built on an analogy between humans and ultrasocial insects. We argue that there are many important limitations to the analogy that make any possible inferences from the analogy questionable. We demonstrate the issue using an example of the difference between a loss of autonomy in humans and in social insects.
Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers
Authors: Florence T.H. Wu, Shan Man, Ping Xu, Annabelle Chow, Marta Paez-Ribes, Christina R. Lee, Steven R. Pirie-Shepherd, Urban Emmenegger, Robert S. Kerbel
Journal: Cancer Research (2016)

Antiangiogenic tyrosine kinase inhibitors (TKI) that target VEGF receptor-2 (VEGFR2) have not been effective as adjuvant treatments for micrometastatic disease in phase III clinical trials. Angiopoietin-2 (Ang2) is a proangiogenic and proinflammatory vascular destabilizer that cooperates with VEGF. The purpose of this study was to test whether CVX-060 (an Ang2-specific CovX-body) can be combined with VEGFR2-targeting TKIs (sunitinib or regorafenib) to successfully treat postsurgical metastatic disease in multiple orthotopically implanted human tumor xenograft and syngeneic murine tumor models. In the MDA-MB-231.LM2-4 human breast cancer model, adjuvant sunitinib was ineffective, whereas adjuvant CVX-060 delayed the progression of pulmonary or distant lymphatic metastases; however, overall survival was only improved with the adjuvant use of a VEGF-A/Ang2-bispecific CovX-body (CVX-241) but not when CVX-060 is combined with sunitinib. Adjuvant CVX-241 also showed promise in the EMT-6/CDDP murine breast cancer model, with or without an immune checkpoint inhibitor (anti-PD-L1). In the RENCA model of mouse renal cancer, however, combining CVX-060 with sunitinib in the adjuvant setting was superior to CVX-241 as treatment for postsurgical lung metastases. In the HCT116 and HT29 xenograft models of colorectal cancer, both CVX-060 and regorafenib inhibited liver metastases. Overall, our preclinical findings suggest differential strategies by which Ang2 blockers can be successfully combined with VEGF pathway targeting in the adjuvant setting to treat micrometastatic disease-particularly, in combination with VEGF-A blockers (but not VEGFR2 TKIs) in resected breast cancer; in combination with VEGFR2 TKIs in resected kidney cancer; and as single agents or with VEGFR2 TKIs in resected colorectal cancer. Cancer Res; 76(23); 6988-7000. ©2016 AACR.
Guidelines for Tinnitus
Authors: David E. Tunkel, Stephanie L. Jones, Richard M. Rosenfeld
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Having a named accountable GP does not improve continuity of care, study finds
Authors: Jacqui Wise
Journal: BMJ (2016)

The government initiative requiring all patients over 75 in England to have a named accountable GP seems to have had no effect on continuity of care, a study published in BMJ Open has found.1

In April 2014 the Quality and Outcomes Framework was reformed, and general practices got an increase in core funding from £66 to £74 per patient per year. At the same time a requirement was added to the contract, stipulating that general practices …
Convergent Transcription of Interferon-Stimulated Genes by TNF-A and IFN-A Augments Antiviral Activity against HCV and HEV
Authors: W. Wang, L. Xu, J. Brandsma, Y. Wang, M. Hakim, X. Zhou, Y. Yin, G. Fuhler, L.J.W. Van Der Laan, C. Janneke Van Der Woude, D. Sprengers, H. Metselaar, R. Smits, R. Poot, M. Peppelenbosch, Q. Pan
Journal: Journal of Hepatology (2016)
The Amount of Preadipocytes in Visceral Adipose Tissue Decreases with Non-Alcoholic Fatty Liver Disease in Morbid Obesity
Authors: A. Carazo, E. Pavón, J. García-Rubio, J.A. Muñoz-Gámez, A. Cózar, M. Caba-Molina, T. Caballero, A. Gila, J. Salmerón
Journal: Journal of Hepatology (2016)
Bilateral Optic Nerve Invasion of Extranodal Marginal Zone B Cell Lymphoma with Leukemic Subtype
Authors: Hwa Jung Sung, Eui Bae Kim, Se Ryeon Lee, Kyong Hwa Park, In Keun Choi, Sang Chul Oh, Byung Soo Kim, Yeul Hong Kim, Jun Suk Kim, Hee Yun Seo, Sun Hyung Kim, Soo-Young Yoon
Journal: Blood (2008)
Clarity: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Lopixibat Chloride (Formerly Lum001), a Novel Apical Sodium-Dependent Bile Acid Transporter Inhibitor, in the Treatment of Primary Biliary Cirrhosis Associated with Itching
Authors: M.J. Mayo, P. Pockros, D. Jones, C. Bowlus, C. Levy, I. Patanwala, B. Bacon, V. Luketic, R. Vuppalanchi, S. Medendorp, A. Dorenbaum, C. Kennedy, P. Novak, A. Raychaudhuri, S. Goyal, W. Abi-Saab, G.M. Hirschfield
Journal: Journal of Hepatology (2016)
Proton Pump Inhibitors Intake and Infection in Cirrhotic Patients: A Multicentric Experience
Authors: C. Teixeira, A. Antunes, C. Martins, A.M. Vaz, P. Queiros, A.L. Alves, B. Peixe, H. Guerreiro, A.P. Oliveira
Journal: Journal of Hepatology (2016)
Role of urokinase-type plasminogen activator in ventricular wall rupture, scar formation, and cardiac function after myocardial infarction
Authors: SB Heymans, Dieter Nuyens, Eejm Creemers, Lieve Moons, Jpm Cleutjens, Mjap Daemen, Jfm Smits, Desire Collen, Peter Carmeliet
Journal: Circulation (1999)
The t(11;18)(q21;q21) characterizes a subgroup of extranodal MALT lymphomas: a two-color fluor-escence in situ hybridization study using AP12 and MLT specific probes
Authors: J Dierlamm, Thijs Baens, M Stefanova, K Hinz, Iwona Wlodarska, Anja Steyls, B Maes, A Driessen, Gregor Verhoef, P Gaulard, Anne Hagemeijer-Hausman, DK Hossfeld, Christiane Peeters, Peter Marynen
Journal: Blood (1999)
Pomalidomide plus low-dose dexamethasone (POM + LoDEX) versus high-dose dexamethasone (HiDEX) in relapsed/refractory multiple myeloma (RRMM): Impact of cytogenetics in MM-003.
Authors: Hartmut Goldschmidt, Meletios A. Dimopoulos, Katja C. Weisel, Philippe Moreau, Martha Lacy, Kevin W. Song, Michel Delforge, Lionel Karlin, Anne Banos, Albert Oriol Rocafiguera, Xin Yu, Lars Sternas, Christian Jacques, Mohamed H. Zaki, Jesùs F. San-Miguel
Journal: Journal of Clinical Oncology (2013)

8528 Background: RRMM patients (pts) who fail lenalidomide (LEN) and bortezomib (BORT) have poor prognosis. High-risk cytogenetics predict shorter survival. POM + LoDEX has demonstrated efficacy in pts with prior LEN and BORT and high-risk cytogenetics. MM-003 is an open-label, multicenter, phase III trial comparing POM + LoDEX vs. HiDEX in RRMM pts who failed LEN and BORT treatment (Tx) and have progressed on their last therapy. Methods: Pts must have been refractory to the last prior Tx (progressive disease [PD] during or within 60 days) and failed LEN and BORT after ≥ 2 consecutive cycles of each (alone or in combination). Randomization was 2:1 to POM 4 mg D1–21 + DEX 40 mg (20 mg for pts aged &gt; 75 y) weekly; or DEX 40 mg (20 mg for pts aged &gt; 75 y) D1–4, 9–12, and 17–20 (28-day cycles). Tx continued until PD or unacceptable adverse events (AEs). The primary endpoint was progression-free survival (PFS). Secondary endpoints included OS and AEs. This analysis examined pts meeting modified high-risk cytogenetic criteria—del(17p13) and/or t(4p16/14q32). Results: 302 pts received POM + LoDEX, and 153 pts received HiDEX. 225 and 107 pts, respectively, were evaluable for cytogenetics. Baseline characteristics were similar. Median PFS and OS were significantly longer with POM + LoDEX vs. HiDEX, regardless of cytogenetic risk (Table). The most common grade 3/4 AEs were neutropenia, anemia, and infection (Table). Discontinuation due to AE was low: 4% vs. 6% (high risk) and 10% vs. 4% (standard risk). Conclusions: Median PFS and OS were significantly longer with POM + LoDEX vs. HiDEX in pts with cytogenetically-defined high-risk disease, consistent with results from the intent-to-treat population. Tolerability was acceptable. POM + LoDEX should be considered a new Tx option in pts failing LEN and BORT. Clinical trial information: NCT01311687. [Table: see text]
Classification and Survival of 179 Patients with T- and NK-Cell Lymphomas at the Federal Research Hematology Center of Russian Academy of Medical Sciences: A Retrospective Study.
Authors: Yulia E. Vinogradova, I.N. Lutsenko, R.S. Samoilova, I.B. Kaplanskaya, Ivan A. Vorobiev, Boris V. Zingerman, N.B. Rijicova, Nikita E. Shklovskiy-Kordi, E.A. Giliazitdinova, Oleg V. Margolin, D.C. Maryin, Alexandra Krementskaya, S.K. Kravchenko, Lyuba Varticovski, Andrei I. Vorobiev
Journal: Blood (2007)
Neoadjuvant chemotherapy in locally advanced gastric cancer with epirubicin, oxaliplatin, and capecitabine (EOX): A retrospective analysis.
Authors: U. Pluschnig, J. Zacherl, S. Schoppmann, M. Raderer, G. Prager, R. Bartsch, A. Ba-Ssalamah, W. Lamm, C. Zielinski, M. Hejna
Journal: Journal of Clinical Oncology (2010)

e14682 Background: Gastric cancer carries a poor prognosis and is one of the leading causes of cancer deaths worldwide. Adjuvant chemotherapy did not result in a survival advantage in Caucasian populations. Thus, other therapeutic options including perioperative chemotherapy were investigated: In the neoadjuvant setting, combinations of epirubicin, cyclophosphamide and fluorouracile or capecitabine as well as cisplatin or oxaliplatin improved outcome versus surgery alone. Here, we report on the use of the EOX regimen in the neoadjuvant setting which had shown a trend in advanced gastric cancer of superior survival outcome. Methods: 20 Patients (median age: 70.5, range 36-85, years; 15 pts > 65 years) with locally advanced adenocarcinoma of the upper GI-tract received 3 courses of perioperative chemotherapy with epirubicin 50 mg/m2, day1, oxaliplatin 130 mg/m2, day 1, and capecitabine 2,000 mg/m2, days 1- 14, of a 3-week cycle. Toxicity was assessed by CTC (Common Toxicity Criteria) for every cycle. Progression free survival (PFS) was defined as interval from surgery to disease progression assessed by PET-CT which was performed at diagnosis and after 3 cycles of chemotherapy and every twelve weeks thereafter. Results: 17 pts completed all three planned cycles of chemotherapy, 2 pts received only one cycle due to rapid tumor progression, 1 patient is currently still on treatment. 11 pts underwent surgery with curative resection with 2 pCRs. 4 pts remained inoperable despite chemotherapy and 3 pts are waiting for surgery. 1 patient died after front-line chemotherapy due to rapid tumor progression. After surgery, 3 pts died after a median of 6.8 (range: 5-8) months. Only 2 pts experienced grade 3-4 toxicities including nausea, diarrhea and hand-foot syndrome and one non-life-threatening pulmonary embolism. Dose reduction of capecitabine to 75% due to toxicity was necessary in 2 pts. PFS was 8.7 month (5.3-12.1 95%CI); overall survival is not reached, yet. Conclusions: We conclude that EOX is a well tolerated, safe, and efficacious as neoadjuvant treatment in elderly patients with locally advanced adenocarcinoma of the upper GI-tract encouraging further investigation. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Roche